YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
From a valuation perspective, Utah Medical Products, Inc. UTMD stock looks expensive. UTMD is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 4.05X, above the industry average of 2.68X. UTMD also trades at a h…
On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company…
NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22…
Telix Pharmaceuticals Limited David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. Dr. Mark Nelson will continue…
Company Logo As the global neurotoxin market expands across cosmetic facial aesthetics and neurological therapeutic applications, Dysport (abobotulinumtoxinA)—developed and commercialized by Ipsen and Galderma—continues to maintain a criti…
Earnings Call Insights: Evolus (EOLS) Q2 2026 MANAGEMENT VIEW * "The second quarter represents a meaningful inflection point for Evolus." (President, CEO & Director David Moatazedi) * "We delivered 21% revenue growth, generated our third c…
ResMed RMD shares rallied 4.2% in the last trading session to close at $218.4. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.9% gain ov…
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Evolus Inc (Symbol: EOLS), where a total volume of 4,005 contracts has been traded thus far today, a contract volume whic…
Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, companies that exhibit high growt…
Evolus, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Operational Context Achieved a second consecutive quarter of positive adjusted EBITDA during a seasonally low revenue period, validating the structural cost improvem…
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This qu…
The United States market has shown robust performance, rising 3.4% over the last week and an impressive 35% over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, growth companies with high insi…
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products wi…
Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Directo…
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expa…
Evolus logo Key Points Evolus says the U.S. botulinum toxin market is stabilizing after the 2024 pullback, expecting low-single-digit growth now with a return to mid-single-digit growth by 2027–2028. Its new HA product, Evolysse, is gainin…
Key Points Demand for Evolus' beauty products is growing. Management expects to generate sustainable profits in 2026.10 stocks we like better than Evolus › Shares of Evolus (NASDAQ: EOLS) climbed on Wednesday after the aesthetics specialis…
[Close up image of wooden cubes with alphabet Q4 on office desk.] mohd izzuan Evolus (EOLS [https://seekingalpha.com/symbol/EOLS]) shares jumped ~36% on Wednesday, its biggest intraday gain in nearly half a decade, after the maker of Jeuve…
Evolus, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Market Positioning Delivered 12% full-year revenue growth despite 2025 being only the third time in 25 years that U.S. injectable volumes declined. Attributed Jeuv…
Earnings Call Insights: Evolus (EOLS) Q4 2025 MANAGEMENT VIEW * CEO David Moatazedi described Evolus' focus on a "performance beauty strategy" centered around a cash-pay aesthetic model, emphasizing differentiation through partnerships and…
Image source: The Motley Fool. Date Tuesday, March 3, 2026 at 4:30 p.m. ET Call participants President and Chief Executive Officer — David Moatazedi Chief Financial Officer — Tatjana Mitchell Chief Medical Officer and Head of R&D — Rui Ave…
Information Technology stocks lead the pack on quant strength in the latest screen, posting the highest average ratings among the sectors listed, while Health Care names rank at the bottom. The single highest-rated stock overall is Impala…
Wall Street expects a year-over-year increase in earnings on higher revenues when Evolus, Inc. (EOLS) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earn…
We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On February 4, Mizuho analyst Uy Ear lowered the firm’s price target on Evolus, Inc. (NASDAQ:EOLS) to $15 from $19 while maintaining an Outperform rating, refl…
Boston Scientific (BSX) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.7 per share a year ago. These figures are adjusted for non-recurring items…
Key Points Oregon-based Stonepine Capital Management reduced its Indivior stake by 250,000 shares in the third quarter. The overall position value fell by about $2.75 million from the previous period. As of September 30, the fund reported…
Key Points Oregon-based Stonepine Capital Management sold all 38,597 shares of its ANI Pharmaceuticals shares in the third quarter. The shares were worth about $2.52 million. The move marked a full exit from ANI, with the fund reporting no…
Evolus Inc. (NASDAQ:EOLS) is one of the stocks that will double in 2026. On December 2, Mizuho lowered the firm’s price target on Evolus to $19 from $20, while keeping an Outperform rating on the shares. Mizuho lowered its estimates for Ev…
Image source: The Motley Fool. Date Wednesday, Nov. 5, 2025, at 4:30 p.m. ET Call participants Chief Executive Officer — David Moatazedi Chief Financial Officer — Tatiana Mitchell Chief Medical Officer and Head of R&D — Rui Avelar Head of…
(RTTNews) - Several healthcare and medtech stocks staged notable rebounds in after-hours trading Wednesday, with gains driven by updated guidance, margin improvements, and signs of operational resilience despite mixed quarterly results. Rx…
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This q…
Wall Street expects a year-over-year decline in earnings on lower revenues when Prestige Consumer Healthcare (PBH) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the…
* Evolus (NASDAQ:EOLS [https://seekingalpha.com/symbol/EOLS]) has appointed Tatjana Mitchell as its chief financial officer, effective September 8, 2025. * EOLS -0.52% premarket to $7.62. * Source: Press Release [https://seekingalpha.com/p…
NEWPORT BEACH, Calif., September 08, 2025--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell a…
[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MOND…
[Wall Street New York stock exchange stock market] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. M…